Giulio Paciotti, Ph.D

Giulio Paciotti, Ph.D, is Chief Science Officer at Zahav Bioscience, where he leads the company’s research on novel cancer nanomedicines. He brings more than 35 years of experience advancing nanoparticle-based diagnostics and therapeutics, with deep expertise spanning tumor biology, immunology, translational development, and cGMP manufacturing.

Dr. Paciotti’s work is grounded in the belief that successful cancer nanomedicines emerge from a deep understanding of cancer biology combined with disciplined translational engineering.

Prior to joining Zahav Bioscience, Dr. Paciotti held senior leadership roles at biotechnology startups, including serving as Chief Science Officer at CytImmune Sciences.

Earlier in his career, Dr. Paciotti conducted foundational research at the National Institutes of Health. He has authored numerous scientific publications and patents across nanotechnology, oncology, and drug delivery.

Paciotti received his BS, MS, and Ph.D from the University of Maryland.

LinkedIn